US FDA approves Roivant-Priovant's skin disease drug
ROIV•FDA approves first oral treatment for dermatomyositis
The U.S. Food and Drug Administration said on Thursday it approved a treatment from Roivant and partner Priovant Therapeutics for dermatomyositis, making it the first oral drug for the skin disease.
